Cargando…

The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients

OBJECTIVE: Colon cancer (CC) is one of the most common cancers worldwide and has a poor prognosis. Surgery followed by adjuvant chemotherapy is the standard treatment strategy for stage III CC patients. Primary tumor location (PTL) is an important factor for the long-term survival of CC. However, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chenghui, Lu, Liqing, Huang, Qiulin, Tang, Zhen, Tang, Rong, Xiao, Zhongsheng, Xiao, Shuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077613/
https://www.ncbi.nlm.nih.gov/pubmed/37020295
http://dx.doi.org/10.1186/s12876-023-02741-3
_version_ 1785020342281961472
author Zhou, Chenghui
Lu, Liqing
Huang, Qiulin
Tang, Zhen
Tang, Rong
Xiao, Zhongsheng
Xiao, Shuai
author_facet Zhou, Chenghui
Lu, Liqing
Huang, Qiulin
Tang, Zhen
Tang, Rong
Xiao, Zhongsheng
Xiao, Shuai
author_sort Zhou, Chenghui
collection PubMed
description OBJECTIVE: Colon cancer (CC) is one of the most common cancers worldwide and has a poor prognosis. Surgery followed by adjuvant chemotherapy is the standard treatment strategy for stage III CC patients. Primary tumor location (PTL) is an important factor for the long-term survival of CC. However, the difference in the prognosis between the histological subtypes of mucinous adenocarcinoma (MAC) and nonspecific adenocarcinoma (AC) in stage III CC patients is unclear. The correlation of chemotherapy, PTL and histological subtype with the overall survival (OS) of stage III CC patients has not yet been explored. METHODS: Patients diagnosed with stage III CC from 2010 to 2016 in the Surveillance, Epidemiology, and End Results (SEER) database were retrieved. The clinicopathological features and OS were analyzed according to the chemotherapy, PTL and histological subtype. RESULTS: A total of 28,765 eligible stage III CC patients were enrolled in this study. The results showed that chemotherapy, left-sided CC (LCC) and AC were favorable prognostic factors for OS. Right-sided CC (RCC) had worse OS than LCC regardless of chemotherapy. MAC had worse OS than AC in the patients with chemotherapy, but the survival benefits disappeared in the patients without chemotherapy. Additionally, in LCC, MAC had worse OS than AC regardless of chemotherapy. However, in RCC, MAC had worse OS than AC in patients with chemotherapy but had similar OS to AC in patients without chemotherapy. In the AC group, RCC had worse OS than LCC regardless of chemotherapy. In the MAC group, RCC had comparable OS to LCC regardless of chemotherapy. Four subgroups, i.e., RCC/MAC, RCC/AC, LCC/MAC and LCC/AC, all showed benefits from chemotherapy. Among them, LCC/AC had the best OS, and RCC/MAC had the worst OS compared with the other three subgroups. CONCLUSION: The prognosis of MAC is worse than that of AC in stage III CC. LCC/AC has the best OS, while RCC/MAC has the worst OS but still benefits from chemotherapy. The impact of chemotherapy on survival is greater than that of histological subtype, but the impact of histological subtype on survival is similar to that of PTL.
format Online
Article
Text
id pubmed-10077613
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100776132023-04-07 The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients Zhou, Chenghui Lu, Liqing Huang, Qiulin Tang, Zhen Tang, Rong Xiao, Zhongsheng Xiao, Shuai BMC Gastroenterol Research OBJECTIVE: Colon cancer (CC) is one of the most common cancers worldwide and has a poor prognosis. Surgery followed by adjuvant chemotherapy is the standard treatment strategy for stage III CC patients. Primary tumor location (PTL) is an important factor for the long-term survival of CC. However, the difference in the prognosis between the histological subtypes of mucinous adenocarcinoma (MAC) and nonspecific adenocarcinoma (AC) in stage III CC patients is unclear. The correlation of chemotherapy, PTL and histological subtype with the overall survival (OS) of stage III CC patients has not yet been explored. METHODS: Patients diagnosed with stage III CC from 2010 to 2016 in the Surveillance, Epidemiology, and End Results (SEER) database were retrieved. The clinicopathological features and OS were analyzed according to the chemotherapy, PTL and histological subtype. RESULTS: A total of 28,765 eligible stage III CC patients were enrolled in this study. The results showed that chemotherapy, left-sided CC (LCC) and AC were favorable prognostic factors for OS. Right-sided CC (RCC) had worse OS than LCC regardless of chemotherapy. MAC had worse OS than AC in the patients with chemotherapy, but the survival benefits disappeared in the patients without chemotherapy. Additionally, in LCC, MAC had worse OS than AC regardless of chemotherapy. However, in RCC, MAC had worse OS than AC in patients with chemotherapy but had similar OS to AC in patients without chemotherapy. In the AC group, RCC had worse OS than LCC regardless of chemotherapy. In the MAC group, RCC had comparable OS to LCC regardless of chemotherapy. Four subgroups, i.e., RCC/MAC, RCC/AC, LCC/MAC and LCC/AC, all showed benefits from chemotherapy. Among them, LCC/AC had the best OS, and RCC/MAC had the worst OS compared with the other three subgroups. CONCLUSION: The prognosis of MAC is worse than that of AC in stage III CC. LCC/AC has the best OS, while RCC/MAC has the worst OS but still benefits from chemotherapy. The impact of chemotherapy on survival is greater than that of histological subtype, but the impact of histological subtype on survival is similar to that of PTL. BioMed Central 2023-04-05 /pmc/articles/PMC10077613/ /pubmed/37020295 http://dx.doi.org/10.1186/s12876-023-02741-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhou, Chenghui
Lu, Liqing
Huang, Qiulin
Tang, Zhen
Tang, Rong
Xiao, Zhongsheng
Xiao, Shuai
The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
title The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
title_full The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
title_fullStr The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
title_full_unstemmed The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
title_short The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
title_sort effects of chemotherapy, primary tumor location and histological subtype on the survival of stage iii colon cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077613/
https://www.ncbi.nlm.nih.gov/pubmed/37020295
http://dx.doi.org/10.1186/s12876-023-02741-3
work_keys_str_mv AT zhouchenghui theeffectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT luliqing theeffectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT huangqiulin theeffectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT tangzhen theeffectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT tangrong theeffectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT xiaozhongsheng theeffectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT xiaoshuai theeffectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT zhouchenghui effectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT luliqing effectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT huangqiulin effectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT tangzhen effectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT tangrong effectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT xiaozhongsheng effectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients
AT xiaoshuai effectsofchemotherapyprimarytumorlocationandhistologicalsubtypeonthesurvivalofstageiiicoloncancerpatients